Form SC 13G/A Protara Therapeutics, Filed by: ORBIMED ADVISORS LLC
Protara Therapeutics, Inc. (TARA)
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
TARA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TARA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TARA alerts
High impacting Protara Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TARA
News
- UK NICE backs Exact's Oncotype cancer genomic test Fri, May 10, 2024, 3:22 PM GMT+2 2 min read 0 In this article: Advertisement Up next These 2 ‘Strong Buy' Penny Stocks Could Surge Over 400%, Says Oppenheimer Thu, May 9, 2024, 7:20 PM GMT+2 6 min read Acquire Media Monitor
- Protara Therapeutics, Inc. (NASDAQ: TARA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.MarketBeat
- Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
- Protara Therapeutics, Inc. (NASDAQ: TARA) had its price target raised by analysts at Oppenheimer Holdings Inc. from $26.00 to $30.00. They now have an "outperform" rating on the stock.MarketBeat
- Here's Why Protara Therapeutics (TARA) Is a Great 'Buy the Bottom' Stock Now [Yahoo! Finance]Yahoo! Finance
TARA
Earnings
- 5/2/24 - Beat
TARA
Sec Filings
- 5/17/24 - Form 4
- 5/10/24 - Form 4
- 5/10/24 - Form EFFECT
- TARA's page on the SEC website